ST. PAUL, Minn. - Patterson Companies, Inc. (NASDAQ:PDCO), a prominent distributor in dental and animal health, is set to be acquired by health care investment firm Patient Square (NYSE:XYZ) Capital, following the expiration of a "go-shop" period on January 19, 2025. The agreement, which was previously announced, will see Patient Square Capital purchasing Patterson at $31.35 per share, in an all-cash transaction valued at roughly $4.1 billion, including the refinancing of Patterson’s receivables facilities.
During the 40-day go-shop period, Patterson had the opportunity to solicit and consider alternative proposals. However, no such proposals were received by the deadline. The transaction is anticipated to close in April 2025, subject to customary closing conditions, including approval from Patterson’s shareholders and antitrust clearance in the U.S. Once the deal is finalized, Patterson will operate as a privately held entity, and its shares will cease to be listed on the NASDAQ Global Select Market.
Patterson Companies has established itself as a connector of customers in North America and the U.K. to a broad range of products, technologies, and business solutions in the dental and animal health sectors. The company has maintained a solid financial position, with InvestingPro analysis showing consistent profitability and a 3.37% dividend yield, having maintained dividend payments for 15 consecutive years. Patient Square Capital, the acquiring firm, manages approximately $11 billion in assets and focuses on investments in health care entities that aim to enhance health outcomes.
The forthcoming acquisition is expected to position Patterson to leverage Patient Square Capital's resources and health care industry expertise, although the specifics of how the transaction will influence Patterson's operations or strategic direction have not been disclosed.
This press release contains forward-looking statements regarding the proposed merger, including the timing and completion of the transaction. It notes that the actual results may differ due to a variety of factors, and emphasizes the risks and uncertainties associated with such forward-looking statements.
Shareholders of Patterson will be asked to vote on the proposed merger at a special meeting, the details of which will be provided in a proxy statement to be filed with the SEC. The statement will offer important information about the merger and will be made available to shareholders for review. According to InvestingPro analysis, Patterson maintains a GOOD overall Financial Health Score, with particularly strong marks in profitability and price momentum. For comprehensive insights into Patterson's financial metrics and more exclusive analysis, investors can access the detailed Pro Research Report, available as part of the InvestingPro subscription.
This news report is based on a press release statement and does not include any assumptions or predictions beyond the information provided.
In other recent news, Patterson Companies has entered into a definitive agreement to be acquired by Patient Square Capital in a deal valued at approximately $4.1 billion. The acquisition agreement stipulates a purchase price of $31.35 in cash for each Patterson share. This development has led to various analyst firms adjusting their stock price targets for Patterson. Baird and Mizuho (NYSE:MFG) Securities have increased their targets to $31, while Leerink Partners raised theirs to $31.35. Despite these adjustments, all three firms maintained a Neutral rating on the stock.
On the other hand, Piper Sandler adjusted its price target for Patterson Companies to $24. The firm's revised earnings guidance midpoint now stands at $2.30 per share. Following the acquisition's completion, Patterson Companies will operate as a privately held entity. These recent developments indicate a significant shift in Patterson Companies' business landscape.
These are recent developments and may have potential implications for investors. Patterson Companies' shareholders are poised to receive $31.35 per share, a figure that now aligns with Jefferies' updated price target. The Hold rating indicates a neutral stance on the stock, suggesting that the analyst believes the current share price adequately reflects the company's value following the acquisition news.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.